These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36209319)

  • 21. [FEES in Infants with Swallowing Disorders - A Feasible Procedure?].
    Böckler R
    Laryngorhinootologie; 2016 Mar; 95(3):192-6. PubMed ID: 26669580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes.
    Dunaway Young S; Pasternak A; Duong T; McGrattan KE; Stranberg S; Maczek E; Dias C; Tang W; Parker D; Levine A; Rohan A; Wolford C; Martens W; McDermott MP; Darras BT; Day JW
    J Neuromuscul Dis; 2023; 10(2):199-209. PubMed ID: 36776075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Vogel A; Claus I; Ahring S; Gruber D; Haghikia A; Frank U; Dziewas R; Ebersbach G; Gandor F; Warnecke T
    Mov Disord; 2022 Mar; 37(3):535-544. PubMed ID: 34773420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
    Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the Italian Version of the Functional Oral Intake Scale (FOIS-It) Against Fiberoptic Endoscopic Evaluation of Swallowing and Nutritional Status.
    Ninfa A; Pizzorni N; Eplite A; Moltisanti C; Schindler A
    Dysphagia; 2022 Feb; 37(1):137-147. PubMed ID: 33591464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.
    Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS
    Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative Assessment of Swallowing Dysfunction in Patients with Spinal and Bulbar Muscular Atrophy.
    Hashizume A; Banno H; Katsuno M; Hijikata Y; Yamada S; Inagaki T; Suzuki K; Sobue G
    Intern Med; 2017 Dec; 56(23):3159-3165. PubMed ID: 29021456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding Endoscopist-Directed Flexible Endoscopic Evaluation of Swallowing to the Videofluoroscopic Swallowing Study Increased the Detection Rates of Penetration, Aspiration, and Pharyngeal Residue.
    Park WY; Lee TH; Ham NS; Park JW; Lee YG; Cho SJ; Lee JS; Hong SJ; Jeon SR; Kim HG; Cho JY; Kim JO; Cho JH; Lee JS
    Gut Liver; 2015 Sep; 9(5):623-8. PubMed ID: 25473074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysphagia diagnosis with questionnaire, tongue strength measurement, and FEES in patients with childhood-onset muscular dystrophy.
    Printza A; Goutsikas C; Triaridis S; Kyrgidis A; Haidopoulou K; Constantinidis J; Pavlou E
    Int J Pediatr Otorhinolaryngol; 2019 Feb; 117():198-203. PubMed ID: 30579082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1381-1389. PubMed ID: 35715566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.
    Matesanz SE; Curry C; Gross B; Rubin AI; Linn R; Yum SW; Kichula EA
    J Child Neurol; 2020 Oct; 35(11):717-723. PubMed ID: 32515646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.